Feed HSDT
HS

Helius Medical Technologies, Inc.

HSDT · NASDAQ

$2.76 +17.45% (+$0.41)
1M +48.39%
Market Cap $133.7M
P/E Ratio -
Div. Yield -
ROE 122.85%
Piotroski F-Score Weak
3/9
Valuation
62 /100
Fair
P/B 0.81x
P/S 11.08x
PEG N/A
Growth
100 /100
Growing
Book val. growth 232.97%
Rev. growth 97.00%
FCF growth N/A
Profitability
0 /100
Weak
Op. margin 200.47%
Net margin 1,302.78%
FCF margin N/A
Quality
13 /100
Poor
ROA 89.33%
Asset turnover 0.07x
ROE 122.85%
Debt
100 /100
Low
Current ratio 13.31x
Debt/Assets N/A
Net debt/EBITDA N/A
Stability
56 /100
Moderate
Profitable years 0
EPS volatility 15.78%
Beta 1.07x

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about HSDT
Online

About the company

Helius Medical Technologies, Inc. is a biopharmaceutical company focused on the development and commercialization of neurostimulation therapies for the treatment of neurological disorders. Its main product platform is the Portable Neuromodulation Stimulator (PoNS) technology, which utilizes tongue stimulation to influence brain function and the nervous system. This technology has the potential to help patients with various neurological disorders, including traumatic brain injury, multiple sclerosis, and other neurological conditions. The company focuses on conducting clinical trials and obtaining regulatory approvals for its therapeutic products. Its goal is to provide innovative and effective treatment methods to improve the quality of life for patients suffering from neurological disorders. Shares of Helius Medical Technologies, Inc. may be an interesting investment opportunity for investors following the biopharmaceutical industry and neurological medicine.

Sector

Financial Services

Industry

Asset Management

CEO

Dane Carl Andreeff

Employees

21

Headquarters

Newtown

Upcoming events

17 NOV

Earnings

Upcoming earnings report

59d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.